Company: SHPH
Filing Date: 2025-02-26
Form Type: 10-K
Source: 0001493152-25-008300
Chunk: 55

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-02-26
Form: 10-K
Item: Item 1
Chunk 55
---
 infringing our intellectual
    property rights;

    ●
    A
    third party may not challenge our patents and, if challenged, a court may not hold that our patents are valid, enforceable and infringed;

    ●
    any
    issued patents that we own or have licensed will provide us with any competitive advantages, or will not be challenged by third parties;

    ●
    we
    may develop additional proprietary technologies that are patentable;

    ●
    the
    patents of others will not have an adverse effect on our business; and

    ●
    our
    competitors do not conduct research and development activities in countries where we do not have enforceable patent rights and then
    use the information learned from such activities to develop competitive products for sale in our major commercial markets.

34

We
intend to license patent rights from third-party owners or licensees. If such owners or licensees do not properly or successfully obtain,
maintain or enforce the patents underlying such licenses, or if they retain or license to others any competing rights, our competitive
position and business prospects may be adversely affected. We may not be able to protect our intellectual property rights throughout
the world.

Obtaining
a valid and enforceable issued or granted patent covering our technology in the U.S. and worldwide can be extremely costly. In jurisdictions
where we have not obtained patent protection, competitors may use our technology to develop their own products and further, may export
otherwise infringing products to territories where we have patent protection, but where it is more difficult to enforce a patent as compared
to the U.S. Competitor products may compete with our future products in jurisdictions where we do not have issued or granted patents
or where our issued or granted patent claims or other intellectual property rights are not sufficient to prevent competitor activities
in these jurisdictions. The legal systems of certain countries, particularly certain developing countries, make it difficult to enforce
patents and such countries may not recognize other types of intellectual property protection, particularly that relating to biopharmaceuticals.
This could make it difficult for us to prevent the infringement of patents or marketing of competing products in violation of our proprietary
rights generally in certain jurisdictions. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial
cost and divert our efforts and attention from other aspects of our business.

We
generally file a provisional patent application first (a priority filing) at the USPTO. A U.S. utility application and international
application under the Patent